A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim Investigational Site, Akita, Akita

Boehringer Ingelheim Investigational Site, Bunkyo-ku, Tokyo

Boehringer Ingelheim Investigational Site, Bunkyo-ku,Tokyo

Boehringer Ingelheim Investigational Site, Habikino, Osaka

Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaraki

Boehringer Ingelheim Investigational Site, Itami, Hyogo

Boehringer Ingelheim Investigational Site, Kamogawa, Chiba

Boehringer Ingelheim Investigational Site, Kishiwada, Osaka

Boehringer Ingelheim Investigational Site, Komaki, Aichi

Boehringer Ingelheim Investigational Site, Kurume, Fukuoka

Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

Boehringer Ingelheim Investigational Site, Matsumoto, Nagano

Boehringer Ingelheim Investigational Site, Morioka, Iwate

Boehringer Ingelheim Investigational Site, Osaka, Osaka

Boehringer Ingelheim Investigational Site, Osakasayama, Osaka

Boehringer Ingelheim Investigational Site, Sakai, Osaka

Boehringer Ingelheim Investigational Site, Sendai, Miyagi

Boehringer Ingelheim Investigational Site, Sendai, Miyagi

Boehringer Ingelheim Investigational Site, Sendai, Miyagi

Boehringer Ingelheim Investigational Site, Seto, Aichi

Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo

Boehringer Ingelheim Investigational Site, Takatsuki, Osaka

Boehringer Ingelheim Investigational Site, Toyonaka, Osaka

Boehringer Ingelheim Investigational Site, Tsukuba, Ibaraki

Boehringer Ingelheim Investigational Site, Wakayama, Wakayama

Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa

Boehringer Ingelheim Investigational Site, Yokote, Akita